Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 3
Submit an article Journal homepage
238
Views
74
CrossRef citations to date
0
Altmetric
Review

Inhibitors of the mammalian target of rapamycin

Janet E Dancey Investigational Drug Branch/CTEP/DCTD, National Cancer Institute, 6130 Executive Boulevard, Room 7131 Rockville, MD 20852, USA. [email protected]
Pages 313-328 | Published online: 22 Apr 2005

Bibliography

  • VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev Cancer (2002) 2(7):489–501.
  • HUANG S, HOUGHTON PJ: Targeting mTOR signalling for cancer therapy. Curr. Opin. Pharmacol (2003) 3(4):371–377.
  • GINGRAS AC, RAUGHT B, SONENBERG N: Control of translation by the target of rapamycin proteins. Frog. Mol. Subcell Biol. (2001) 27:143–174.
  • BRUGAROLAS J, LEI K, HURLEY RL et al.: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumour suppressor complex. Genes Dev. (2004) 18(23):2893–2904.
  • EDINGER AL, LINARDIC CM, CHIANG GG, THOMPSON CB, ABRAHAM RT: Differential effects of rapamycin on mammalian target of rapamycin signalling functions in mammalian cells. Cancer Res. (2003) 63(23):8451–8460.
  • HAY N, SONENBERG N: Upstream and downstream of mTOR. Genes Dev. (2004) 18(16):1926–1945.
  • KWIATKOWSKI DJ: Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. (2003) 67\(Part 1):87–96.
  • KWIATKOWSKI DJ: Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther. (2003) 2(5):471–476.
  • MANNING BD, CANTLEY LC: United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. (2003) 31(3):573–578.
  • INOKI K, LI Y, XU T, GUAN KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. (2003) 17(15):1829–1834.
  • INOKI K, LI Y, ZHU T, WU J, GUAN KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. (2002) 4(9):648–657.
  • GAO X, ZHANG Y, ARRAZOLA P et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell. Biol. (2002) 4(9):699–704.
  • BRUGAROLAS J, KAELIN WG Jr: Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 6(1):7–10.
  • CORRADETTI MN, INOKI K, BARDEESY N, DEPINHO RA, GUAN KL: Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. (2004) 18(13):1533–1538.
  • MANNING BD, CANTLEY LC: Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. (2003) 28(11):573–576.
  • HENGSTSCHLAGER M, ROSNER M, FOUNTOULAKIS M, LUBEC G: Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. Biochem. Biophys. Res. Comm. (2003) 312(3):676–683.
  • LI Y, INOKI K, VACRATSIS P, GUAN KL: The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3.1 Biol. Chem. (2003) 278(16):13663–13671.
  • LIU MY, CATS, ESPEJO A, BEDFORD MT, WALKER CL: 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site (s). Cancer Res. (2002) 62(22):6475–6480.
  • HARA K, MARUKI Y, LONG X et al.: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 110(2):177–189.
  • KIM DH, SARBASSOV DD, ALT SM et al: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 110(2):163–175.
  • LOEWITH R, JACINTO E, WULLSCHLEGER S etal.: Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell (2002) 10(3):457–468.
  • ABRAHAM RT: Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol (1998) 10(3):330–336.
  • BROWN EJ, SCHREIBER SL: A signaling pathway to translational control. Cell (1996) 86(4):517–520.
  • BJORNSTI MA, HOUGHTON PJ: The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer (2004) 4(5):335–348.
  • DENNIS PB, FUMAGALLI S, THOMAS G: Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr. Opin. Genet. Dev. (1999) 9(1):49–54.
  • HOLLAND EC, SONENBERG N, PANDOLFI PP, THOMAS G: Signaling control of mRNA translation in cancer pathogenesis. Oncogene (2004) 23(18):3138–3144.
  • YOKOGAMI K, WAKISAKA S, AVRUCH J, REEVES SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. (2000) 10(1):47–50.
  • DE GROOT RP, BALLOU LM, SASSONE-CORSI P: Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell (1994) 79(1):81–91.
  • BLOMMAART EF, LUIKEN JJ, BLOMMAART PJ, VAN WOERKOM GM, MEIJER AJ: Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. (1995) 270(5)2320–2326.
  • SHIGEMITSU K, TSUJISHITA Y, HARA K et al: Regulation of translational effectors by amino acid and mammalian target of rapamycin signaling pathways. Possible involvement of autophagy in cultured hepatoma cells. J. Biol. Chem. (1999) 274(2):1058–1065.
  • EDINGER AL, THOMPSON CB: Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell. (2002) 13(7):2276–2288.
  • HARADA H, ANDERSEN JS, MANN M, TERADA N, KORSMEYER SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA (2001) 98(17):9666–9670.
  • PENG T, GOLUB TR, SABATINI DM: The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Biol. (2002) 22(15):5575–5584.
  • GAO N, ZHANG Z, JIANG BH, SHI X: Role of P13-K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Comm. (2003) 310(4):1124–1132.
  • MAYERHOFER M, VALENT P, SPERRWR, GRIFFIN JD, SILLABER C: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-la, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood (2002) 100(10):3767–3775.
  • HUMAR R, KIEFER FN, BERNS H, RESINK TJ, BATTEGAY EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB (2002) 16(8):771–780.
  • HUDSON CC, LIU M, CHIANG GG et al.: Regulation of hypoxia-inducible factor la expression and function by the mammalian target of rapamycin. Mol. Biol. (2002) 22(20):7004–7014.
  • RUGGERO D, PANDOLFI PP: Does the ribosome translate cancer? Nat. Rev Cancer (2003) 3(3):179–192.
  • LI S, SONENBERG N, GINGRAS AC et al.: Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell. Biol. (2002) 22(8):2853–2861.
  • RAJASEKHAR VK, VIALE A, SO CCI ND et al.: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell (2003) 12(4):889–901.
  • AVDULOV S, LI S, MICHALEK V et al: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 5(6):553–563.
  • BJORNSTI MA, HOUGHTON PJ: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 5(6):519–523.
  • DOUROS J, SUFFNESS M: New antitumor substances of natural origin. Cancer Treat. Rev (1981) 8(1):63–87.
  • OSHIRO N, YOSHINO K, HIDAYAT S et al: Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells (2004) 9(4):359–366.
  • YONEZAWA K, TOKUNAGA C, OSHIRO N, YOSHINO K: Raptor, a binding partner of target of rapamycin. Biochem. Biophys. Res. Comm. (2004) 313(2):437–441.
  • GIBBONS JJ, DISCAFANI C, PETERSON R et al: The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc. Amer. Assoc. Cancer Res. (1999) 40:(Abstract 2000).
  • GEOERGER B, KERR K, TANG CB et al.: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumorimedulloblastoma models as single agent and in combination chemotherapy. Cancer Res. (2001) 61(4):1527–1532.
  • ESHLEMAN JS, CARLSON BL, MLADEK AC et al: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. (2002) 62(24):7291–7297.
  • GRUNWALD V, DEGRAFFENRIED L, RUSSEL D et al.: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. (2002) 62(21):6141–6145.
  • SHI Y, GERA J, HU L et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. (2002) 62(17):5027–5034.
  • SHI Y, FRANKEL A, RADVANYI LG et al.: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. (1995) 55(9):1982–1988.
  • DECKER T, HIPP S, RINGSHAUSEN I et al.: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood (2003) 101(1):278–285.
  • ALBERS MW, WILLIAMS RT, BROWN EJ et al: FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin Dl-Cdk association in early G1 of an osteosarcoma cell line. J. Biol. Chem. (1993) 268(30):22825–22829.
  • LUO Y, MARX SO, KIYOKAWA H et al.: Rapamycin resistance tied to defective regulation of p27k'Pl. Mol. Cell. Biol. (1996) 16(12):6744–6751.
  • ZEZULA J, SEXL V, HUTTER C et al: The cyclin-dependent kinase inhibitor p21c'P1 mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells. I Biol. Chem. (1997) 272(47):29967–29974.
  • HUANG S, LIU LN, HOSOI H et al: p53/p21(CIP1) cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to 325 Expert Op/n. lnvestig. Drugs (2005) 14(3) rapamycin. Cancer Res. (2001) 61(8):3373–3381.
  • HUANG S, SHU L, EASTON J et al.: Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem. (2004) 279(35):36490–36496.
  • HUANG S, SHU L, DILLING MB et al: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21 (Cipl) . Mol. Cell (2003) 11(6):1491–1501.
  • GUBA M, VON BREITENBUCH P, STEINBAUER M et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. (2002) 8(2):128–135.
  • ZHONG H, HANRAHAN C, VAN DER POEL H, SIMONS JW: Hypoxia-inducible factor la and lb proteins share common signalling pathways in human prostate cancer cells. Biochem. Biophys. Res. Comm. (2001) 284(2):352–356.
  • ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor la expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. (2000) 60(6):1541–1545.
  • HUANG S, HOUGHTON PJ: Mechanisms of resistance to rapamycins. Drug Resist. Updat. (2001) 4(6):378–391.
  • HUANG S, BJORNSTI MA, HOUGHTON PJ: Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. (2003) 2(3):222–232.
  • NOH WC, MONDESIRE WH, PENG J et al.: Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. (2004) 10(3):1013–1023.
  • NESHAT MS, MELLINGHOFF IK, TRAN C et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA (2001) 98(18):10314–10319.
  • PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. ScL USA (2001) 98(18):10320–10325.
  • SHAH 0J, HUNTER T: Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J. Biol. Chem. (2004) 279(20):20816–20823.
  • INOKI K, CORRADETTI MN, GUAN KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. (2005) 37(1):19–24.
  • ZHANG H, CICCHETTI G, ONDA H et al: Loss of Tscl/Tsc2 activates mTOR and disrupts P13-K-Akt signaling through downregulation of PDGFR. j Clin. Invest. (2003) 112(8):1223–1233.
  • WENDEL HG, LOWE SW: Reversing drug resistance in vivo. Cell Cycle (2004) 3(7):847–849.
  • LI S, TAKASU T, PERLMAN DM et al: Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J. Biol. Chem. (2003) 278(5):3015–3022.
  • WENDEL HG, DE STANCHINA E, FRIDMAN JS et al.: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 428(6980):332–337.
  • ENG CP, SEHGAL SN, VEZINA C: Activity of rapamycin (AY-22,989) against transplanted tumors. AntibioL (1984) 37(10):1231–1237.
  • MUTHUKKUMAR S, RAMESH TM, BONDADA S: Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation (1995) 60(3):264–270.
  • SEUFFERLEIN T, ROZENGURT E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. (1996) 56(143895–3897.
  • HOSOI H, DILLING MB, LIU LN et al: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. (1998) 54(5):815–824.
  • HOSOI H, DILLING MB, SHIKATA T et al.: Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. (1999) 59(4):886–894.
  • GREWE M, GANSAUGE F, SCHMID RM, ADLER G, SEUFFERLEIN T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. (1999) 59(15):3581–3587.
  • MAJEWSKI M, KORECKA M, KOSSEV P et al.: The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Nati Acad. Sci. USA (2000) 97(8):4285–4290.
  • DUDKIN L, DILLING MB, CHESHIRE PJ et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. (2001) 7(6):1758–1764.
  • AGUIRRE D, BOYA P, BELLET D et al: Bc1-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis (2004) 9(6):797–805.
  • DEGRAFFENRIED LA, FRIEDRICHS WE, RUSSELL DH et al.: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. (2004) 10(23):8059–8067.
  • DANCEY J: Rapamycin-sensitive signal-transduction pathways. In: Protein translation control of cell proliferation. Lippincott Williams & Wilkins, Alexandria, Virginia, USA (2000):68–75.
  • NEUHAUS P, KLUPP J, LANGREHR JM: mTOR inhibitors: an overview. Liver Transpl. (2001) 7(6):473–484.
  • RAYMOND E, ALEXANDRE J, FAIVRE S et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with caricer.j Clin. Oncol. (2004) 22(12):2336–2347.
  • MITA MM, ROWINSKY EK, GOLDSTON ML et al: Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP-23573, an mTOR Inhibitor, administered iv. daily x 5 every other week in patients (pts) with refractory or advanced malignancies. Proc. Am. Soc. Clin. Omni (2004) 23:Abstract 3076.
  • MITA MM, ROWINSKY EK, MITA AC et al: Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP-23573, an mTOR Inhibitor, administered iv. daily x 5 every other week in patients (pts) with refractory or advanced malignancies. E J.C. 16th EORTC-NC1-326Expert Op/n. Investig. Drugs (2005) 14(3) AACR Symposium on Molecular Targets and Cancer Therapeutics (2004) 2(8):(Abstract 409).
  • CLACKSON T, METCALF CA, RIVERA VM et al: Broad anti-tumor activity of AP-23573, an mTOR inhibitor in clinical development. Proc. Am. Soc. Clin. Oncol (2003) 22 (Abstract 882).
  • LENNON A, FINAN K, FITZGERALD MX, McCORMICK PA: Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation (2001) 72(6):1166–1167.
  • ATKINS MB, HIDALGO M, STADLER W et al.: A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol (2002) 21:(Abstract 36).
  • HIDALGO M, ERIC ROWINSKY E, ERLICHMAN C et al.: A phase land pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. Ann. Oncol (2000) 11\(Suppl. 4):133 (Abstract 6060).
  • HIDALGO M, ROWINSKY E, ERLICHMAN C et al.: Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. Proceedings of the 11th NCI EORTC AACR Symposium on New Drugs in Cancer Therapy Clin. Cancer Res. (2000) 6:(Abstract 413).
  • CHANG SM, KUHN J, WEN P et a/.: Phase 1/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs (2004) 22(4):427–435.
  • FOROUZESH B, BUCKNER J, ADJEI A et al.: Phase I, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies. E. .I.C. (2002) 38\(Suppl. 7):(Abstract 168).
  • ATKINS MB, HIDALGO M, STADLER WM et al.: Randomized Phase II Study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Clin. Oncol (2004) 22(5):909–918.
  • CHAN S, JOHNSTON S, SCHEULEN ME et al: First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol (2002) 21:Abstract 175.
  • CHAN S, SCHEULEN ME, JOHNSTON S et al: Phase II study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens. Proc Am. Soc. Clin. Oncol (2003) 22:(Abstract 774).
  • CHAN S: Targeting the mammalian targetof rapamycin (mTOR): a new approach to treating cancer. BE J. Cancer (2004) 91(8):1420–1424.
  • WITZIG TE, GEYER SM, SALIM M et al.: A Phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: interim analysis of 18 patients. Proc. Am. Soc. Hematol (2003) 102:(Abstract 2374).
  • PERALBA JM, DEGRAFFENRIED L, FRIEDRICHS W et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. (2003) 9(8):2887–2892.
  • MUISE-HELMERICKS RC, GRIMES HL, BELLACOSA A et al: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. j Biol. Chem. (1998) 273(45):29864–29872.
  • TAKUWA N, FUKUI Y, TAKUWA Y: Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(56K) -independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell Biol. (1999) 19(2):1346–1358.
  • DUTCHER JP, HUDES G, MOTZER R et al.: Preliminary report of a Phase 1 study of intravenous (iv.) CCI-779 given in combination with interferon-a (IFN) to patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. GM Oncol (2003) 22:(Abstract 854).
  • PUNT CJ, BONI J, BRUNTSCH U, PETERS M, THIELERT C: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann. Oncol (2003) 14(6):931–937.
  • O'DONNELL A, FAIVRE S, JUDSON I et al.: A phase I study of the oral mTOR inhibitor RAD-001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Oncol (2003) 22:(Abstract 803).
  • LANE H, TANAKA C, KOVARIK J et al: Preclinical and clinical pharmacokinetic/ pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD-001, in oncology. Proc. Am. Soc. Clin. Oncol (2003) 22:(Abstract 951).
  • DI COSIMO S, MATAR P, ROJO F et al: The mTOR pathway inhibitor RAD-001 induces activation of AKT which is completely abolished by Gefitinib, an anti-EGFR tyrosine kinase inhibitor, and combined sequence specific treatment results in greater antitumor activity. Proc. Am. Assoc. Cancer Res. (2004)45:(Abstract 5345).
  • BOULAY A, ZUMSTEIN-MECKER S, STEPHAN C et al.: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD-001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. (2004) 64(1):252–261.
  • PACEY S, READ, STEVEN N et al: Results of a Phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD-001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. Proc. Am. Soc. Chi'. Oncol (2004) 22:(Abstract 3120).
  • GARCIA VD, FILHO JL, NEUMANN J et al.: Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl. Int. (2003) 16(3):202–206.
  • GARCIA VD, BONAMIGO-FILHO JS, NEUMANN J et al.: Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases. Transplant Proc. (2002) 34(7):2993–2995.
  • METCALF III CA, BOHACEK R, ROZAMUS LW et al.: Structure-based design of AP-23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc. Am. Assoc. Cancer Res. 45:(Abstract 2476).
  • RIVERA VM, TANG H, METCALF CA III et al.: Anti-proliferative activity of the mTOR inhibitor AP-23573 in combination with cytotoxic and targeted agents. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 3887).
  • DESAI AA, JANISCH L, BERK LR et al: A phase I trial of a novel mTOR inhibitor AP-23573 administered weekly (wkly) in patients (pts) with refractory or advanced a327 malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc. Am. Soc. Clin. Oncol (2004) 23:(Abstract 3150).
  • DESAI AA, JANISCH L, BERK LR et al.: A Phase I trial of weekly (wkly) AP-23573, a novel mTOR inhibitor, in patients (pts) with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmadynamic (PD) analysis. Eur. j Cancer. (Suppl.) 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (2004) 2(8):(Abstract 390).
  • RIVERA V, BERK L, MITA M et al: Pharmacodynamic evaluation of the mTOR inhibitor AP-23573 in phase 1 clinical trials. Eur. I Cancer. (Suppl.) 16th EORTC-NCIAACR Symposium on Molecular Targets and Cancer Therapeutics (2004) 2(8):(Abstract 411).

Website

  • http://clinicaltrials.gov Information on clinical trials supplied by the US National Institute of Health.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.